Fall 2022 Research Highlights

Highlighted Publications A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease. In this Phase 1 single-center, open-label study of the novel red-cell pyruvate kinase (PKR) activator mitapivat (AG-348) for the...